This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer Invasive Nos
and you are
over 18
years old
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

GEI-BEV-2011-01 is an Observational multicenter study. The study, involving 200 (100 non-responders and 100 best responders) metastatic breast cancer patients, will search for specific genetic variants (SNPs) and miRNA signatures associated with bevacizumab response. Only patients suffering from metastatic (disseminated at the time of diagnosis) breast cancer, treated with bevacizumab, will be included. 1. -To identify genetic variants as bevacizumab response predictors in metastatic breast cancer 2. To identify miRNA signatures in whole blood as bevacizumab response predictors in metastatic breast cancer patients. The main endpoint will be progression-free survival (PFS) The duration of the study will be approximately 18 months

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01598285. The sponsor of the trial is Spanish Breast Cancer Research Group and it is looking for 26 volunteers for the current phase.
Official trial title:
A Combined Genome-Wide Association Study (GWAS) and microRNA (miRNA) Profiling Approach for the Identification of Bevacizumab Response Predictors in Metastatic Breast Cancer